Efficacy and safety of adjuvant therapy with nivolumab or placebo in high-risk patients with muscle-invasive urothelial carcinoma after radical surgery: review of the first results of the randomized phase III trial CheckMate 274

Cover Page

Cite item

Full Text

Abstract

This article analyzes first results of the randomized phase III clinical trial CheckMate 274 that has demonstrated the advantage of adjuvant immunotherapy with nivolumab, a PD-1 inhibitor, over placebo in high-risk patients with muscle-invasive urothelial carcinoma after radical surgery

About the authors

M. I. Volkova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: mivolkova@rambler.ru
ORCID iD: 0000-0001-7754-6624

24 Kashirskoe Shosse, Moscow 115478.

Russian Federation

A. S. Olshanskaya

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0003-0389-564X

24 Kashirskoe Shosse, Moscow 115478; 1 Ostrovityanova St., Moscow 117997.

Russian Federation

S. A. Kalinin

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-0694-7911

1 Ostrovityanova St., Moscow 117997.

Russian Federation

References

  1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1):7-30. doi: 10.3322/caac.21332.
  2. Kamat A.M., Hahn N.M., Efstathiou J.A. et al. Bladder cancer. Lancet 2016;388(10061):2796-810. doi: 10.1016/S0140-6736(16)30512-8.
  3. Clinical guideline. Bladder cancer. Russian National Union “Russian Association of Oncologists”, 2021. (In Russ.).
  4. Flaig T.W., Spiess P.E., Agarwal N. et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020;18(3): 329-54. doi: 10.6004/jnccn.2020.0011.
  5. Witjes J.A. (Chair), Bruins H.M., Cathomas R. et al. Muscle-invasive and Metastatic Bladder Cancer. EAU Guidelines. 2020. Available at: https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/#9.
  6. Raj G.V., Karavadia S., Schlomer B. et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2011;117(2):276-82. doi: 10.1002/cncr.25429.
  7. Donat S.M., Shabsigh A., Savage C. et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol 2009;55(1):177-86. doi: 10.1016/j.eururo.2008.07.018.
  8. Rosenberg J.E., Hoffman-Censits J., Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinumbased chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4.
  9. Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015-26. doi: 10.1056/NEJMoa1613683.
  10. Massard C., Gordon M.S., Sharma S. et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016;34(26):3119-25. doi: 10.1200/JCO.2016.67.9761.
  11. Apolo A.B., Infante J.R., Hamid O. et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: analysis of safety, clinical activity, and PD-L1 expression [abstract]. J Clin Oncol 2016;34:4514.
  12. Sharma P., Retz M., Siefker-Radtke A. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18(3):312-22. doi: 10.1016/S1470-2045(17)30065-7.
  13. Necchi A., Raggi D., Gallina A. et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol 2020;77(4):439-46. doi: 10.1016/j.eururo.2019.10.026.
  14. Powles T., Rodriguez-Vida A., Duran I. et al. A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). JCO 2018;36(15_suppl).
  15. Bajorin D.F., Witjes J.A., Gschwend J.E. et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab versus placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma. Oral presentation at the 2021 Genitourinary Cancers Symposium (ASCO GU). February 11-13, 2021; Virtual Meeting.
  16. Kim H.S., Jeong C.W., Kwak C. et al. Disease-free survival at 2 and 3 years is a significant early surrogate marker predicting the 5-year overall survival in patients treated with radical cystectomy for urothelial carcinoma of the bladder: external evaluation and validation in a cohort of Korean patients. Front Oncol 2015;5:246. doi: 10.3389/fonc.2015.00246.
  17. Sonpavde G., Khan M.M., Lerner S.P. et al. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol 2011;185(2):456-61. doi: 10.1016/j.juro.2010.09.110.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.